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Elevated plasma levels of transforming growth factor
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Germany
Summary Overexpression oftransforming growth factor-4 isoforms (TGF-f1, -P2, -,B3) has been previously reported in human melanoma cell
lines and tumours. The aim of the present study was to evaluate the plasma levels of TGF-f isoforms in melanoma patients. Significantly
elevated levels of TGF-,1l (4.2 x the controls, P= 0.0094) and of TGF-,2 (1.5 x the controls, P= 0.012) but not of TGF-13 were measured in
patients with disseminated but not locoregional melanoma. These results indicate systemic circulation of potentially immunosuppressive
peptides of theTGF-P family in end-stage melanoma patients.
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Transforming growth factor beta 1, beta 2 and beta 3 (TGF-1,
-P2, -[3) are members of a superfamily of multifunctional poly-
peptides that control cell growth and differentiation (Massague,
1990). TGF-[3 may promote angiogenesis and wound healing and
also acts as a potent immunosuppressive factor by inhibiting
proliferation of bone marrow progenitor cells, of T- and B-cell
lineages as well as their functions, including B-cell immunoglob-
ulin synthesis, lymphokine-activated killer (LAK) cytotoxicity,
natural killer (NK) cytotoxicity and T-cell cytotoxicity (Wahl et al,
1989). Overexpression of TGF-P and loss of growth inhibition
have been described in melanoma cell lines in vitro (MacDougall
et al, 1993; Krasagakis et al, 1994; Rodeck et al, 1994). In vivo,
TGF-f31 mRNA has been detected in metastatic nodules, and
increased TGF-12 mRNA expression has been reported in deep
invasive primary tumours (Luscher et al, 1994; Reed et al, 1994).
Furthermore, increased expression ofTGF-,B1, -[2 and -[3 protein
was observed in lesions of invasive primary melanomas and in
metastatic nodules compared with melanocytes, and of TGF-132
and -13 in lesions of melanoma metastases compared with naevi
(Van Belle et al, 1996). These results suggest a relation ofTGF-3
isoforms with tumour progression in situ and raise the question
whether patients with malignant melanoma have elevated circu-
lating levels ofTGF-[ isoforms and whether an association occurs
with tumour progression. We therefore determined the plasma
levels ofTGF-[3l, -[2 and -P3 isoforms in patients with malignant
melanoma ofdifferent tumour stages.
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MATERIALS AND METHODS
Blood samples from 25 malignant melanoma patients before treat-
ment and 12 healthy volunteers were collected, after informed
consent, in ethylenediamine tetraacetic acid (EDTA)-containing
tubes kept on ice, and were immediately centrifuged at 3000 g for
20 min. Plasma samples were kept frozen at -70°C until assayed.
A total of 13 of the patients had locoregional disease (four with
primary tumour alone and nine with regional lymph node involve-
ment) and 12 had distant metastatic spread. For the assays, the
plasma was treated with 2.5 N acetic acid/10 M urea followed by
2.7 N sodium hydroxide/I M N-(-2-hydroxyethyl)-piperazine-N'-
(2-ethanesulphonic acid) (Hepes) for assessment of total plasma
TGF-13 isoforms (active and latent forms).
TGF-P1 and -[32 were measured with commercially available
enzyme-linked immunosorbent assays (ELISAs, R&D Systems,
Minneapolis, MN, USA); for TGF-[3, a sandwich ELISA
technique using goat polyclonal anti-TGF-P3 antibody (R&D
Systems) as the coating reagent has been used. Plasma samples, if
necessary diluted with phosphate-buffered saline (PBS, Biochrom,
Berlin) and 0.1% bovine serum albumin (BSA, Sigma, Deisen-
hofen, Germany), were added to 96-well microtitre antibody-
coated plates and incubated for 90 min. After several washes with
washing buffer (WB), which was PBS with 0.5% BSA and 0.2%
Triton X-100, the second antibody (rabbit polyclonal antibody
detecting an epitope corresponding to amino acids 350-375
mapping at the carboxy terminus of the precursor form of human
TGF-P3) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), was
added for 60 min. After repeated washes with WB, the third anti-
body (horseradish peroxidase conjugated goat anti-rabbit IgG
F(AB')2 fraction from Medac Diagnostika, Hamburg) was applied
for 60 min. After several washes with WB, the chromogenic
substrate O-diphenylenediamine dihydrochloride (Sigma) was
added to the wells. After 20 min the reaction was stopped using
3 M sulphuric acid, and extinction at 490 nm was measured photo-
metrically with an ELISA reader. The ELISA detected recombi-
nant human TGF-f3 (R&D Systems) with a sensitivity of
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Statistical analysis was performed with SPSS package and
significance levels were corrected for multiple tests in pairwise
comparisons between more than two groups (Conover procedure).
A P-value of0.017 is consistent for an overall type I error of0.05
when comparing controls, locoregional melanoma and dissemi-
nated melanoma patients, and the P-value remains 0.05 when
comparing controls with all melanoma patients.
RESULTS
The median plasma TGF-[1 level for all melanoma patients
examined was 13.900 pg ml-' (25th percentile, 8.020 pg ml-'; 75th
percentile, 36.400 pg ml-1) and did not differ significantly from
that found in controls (median, 8.150 pg ml-'; 25th percentile,
3.950 pg ml-'; 75th percentile, 18.890 pg ml-'; P = 0.080,
Mann-Whitney test). However, when assessed according to
subgroups, the TGF-[1 levels measured were significantly higher
in patients with distant melanoma metastasis than in controls
(median, 34.500 pg ml-'; 25th percentile, 9.850 pg ml-'; 75th
percentile, 46.080 pg ml-'; P = 0.0094; seeFigure 1). No statistical
difference was found between patients with locoregional
melanoma and controls. Also, the plasma levels of TGF-j32
(median, 193 pg ml-'; 25th percentile, 163 pg ml-'; 75th
percentile, 253 pg ml-'; controls) were found significantly
elevated in all disconcerted melanoma patients (median, 281 pg
ml-'; 25th percentile, 208 pg ml-'; 75th percentile, 307 pg ml-';
P = 0.031), particularly in patients with distant melanoma metas-
tasis (median, 285 pg ml-'; 25th percentile, 239pg ml-'; 75th
percentile, 363 pg ml-'; P = 0.012). Plasma TGF-[B2 in patients
with locoregional involvement did not differ statistically from the
control values (see Figure 1). The plasma levels ofTGF-[3 were
found unaltered in melanoma patients (median, 290 pg ml-'; 25th
percentile, 0 pg ml-'; 75th percentile, 847 pg ml-') vs controls
(median, 189 pg ml-'; 25th percentile, 0 pg ml-'; 75th percentile,
824 pg ml-'; P = 0.619), irrespective ofthe disease stage.
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Figure 1 Plasma levels ofTGF-01, -02 and -f3 in malignant melanoma
patients compared with controls. Box contains 50% of the 25th-75th
percentile values. Median values are shown by horizontal lines. Lines outside
the box extend to the highest and lowest values, excluding outliers identified
by a circle and extremes shown by an asterisk
62.5 pg ml'. For evaluating cross reactivity with other cytokines,
ELISAs were performed using TGF-J3 as standard, and assessed
the possible cross-immunoreactivity of the combination of the
antibodies with different dilutions (0-50 ng ml-') of other
cytokines. The ELISA did not show detectable cross-reactivity to
dilutions of TGF-[I and TGF-12 or to other cytokines, including
epidermal growth factor, TGF-a, nerve growth factor, basic
fibroblast growth factor, platelet-derived growth factor, interleukin
(IL)-1 , IL-2, IL-3, IL-4, IL-5, IL-6, tumour necrosis factor
(TNF)-a and TNF-[ at a tested range of50 ng ml-'.
DISCUSSION
The source of elevated plasma levels of TGF-,31 and TGF-[B2 is
possibly tumour derived. TGF-11 was shown to be the major
secreted isoform in vitro, although in some cases TGF-133 was
found; small amounts of TGF-[32 were specifically secreted by
melanoma cells and not by benign melanocytes (Krasagakis et al,
1997). Furthermore, increased in situ expression of TGF-f1, -[32,
and -[B3 has been reported in melanoma lesions during melanoma
progression (van Belle et al, 1996), suggesting that these circu-
lating factors are tumour derived and probably accumulate as a
consequence of the increased tumour load in advanced disease
stages.
The present findings support the hypothesis that elevated TGF-
[1 and TGF-[32 plasma levels do correlate with advanced
melanoma progression and may be indicative for the unfavourable
prognosis at this tumour stage. Elevated levels of TGF-[i1 have
been reported in patients with other types of neoplasia, including
colorectal and prostatic carcinoma, indicating disease progression
(Ivanovic et al, 1995; Tsushima et al, 1996). The present data show
for the first time elevated TGF-[B peptide levels in melanoma
patients, and also that, besides TGF-[B1, other TGF-[B isoforms
such as TGF-[2 may be increased in plasma of cancer patients.
Elevated levels ofTGF-[B1 and TGF-,B2 may reflect or, because of
the potent immunosuppressive properties of TGF-P, be even
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causatively involved in the impairment of the immune system in
melanoma patients with advanced tumour dissemination. Indeed,
several lines of evidence suggest a role for tumour-derived TGF-
[3-mediated immunosuppression. A highly immunogenic tumour
transfected with amurine TGF-j1 cDNA escaped immune surveil-
lance in mice, and TGF-[2 has been identified as the T-cell
suppressor factor of human glioblastoma (de Martin et al, 1987;
Torre-Amione et al, 1990). Furthermore, treatment of mice with
anti-TGF-[B antibodies inhibited growth of human breast cancer
cells by enhancing spleen NK-cell activity (Arteaga et al, 1993). In
addition, B16 melanoma growth and metastasis in vivo was inhib-
ited by treatment ofmice with anti-transforming growth factorbeta
antibody and interleukin 2 (Wojtowicz-Praga et al, 1996), indi-
cating that therapeutic interventions for blocking systemic TGF-[B
overexpression should be taken under further consideration.
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